Literature DB >> 15476275

Type I collagen synthesis parallels the conversion of keratinocytic intraepidermal neoplasia to cutaneous squamous cell carcinoma.

Léon C L T van Kempen1, Jos Rijntjes, An Claes, Willeke A M Blokx, Marie-Jeanne P Gerritsen, Dirk J Ruiter, Goos N P van Muijen.   

Abstract

Neoplastic progression of solid tumours is often characterized by a simultaneous increase in matrix protein (eg collagen) synthesis and degradation, and results in the formation of a tumour stroma. At the tumour periphery, this process is believed to facilitate angiogenesis and invasive growth of tumour cells. In various types of carcinoma, differentiation of fibroblasts towards myofibroblasts is thought to play an important role in extracellular matrix remodelling as their emergence coincides with architectural changes in the tumour stroma. Here, distinct architectural changes in collagen fibres are reported in cutaneous squamous cell carcinomas (cSCC) with respect to normal skin and precursor lesions, ie keratinocytic intraepidermal neoplasia (KIN). Simultaneously, type I collagen mRNA was observed in fibroblasts in close proximity to cSCC lesions (19/19) but only in 2 of 10 KIN lesions tested. Interestingly, whereas emerging of myofibroblasts correlated with reduced differentiation of cSCCs, it was not a prerequisite for type I collagen synthesis. These data indicate that type I collagen synthesis by fibroblasts parallels the malignant transformation of human KIN to cSCC. Copyright (c) 2004 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476275     DOI: 10.1002/path.1659

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  8 in total

1.  Stochastic modelling of biased cell migration and collagen matrix modification.

Authors:  Andreas Groh; Alfred K Louis
Journal:  J Math Biol       Date:  2009-12-10       Impact factor: 2.259

2.  A quantitative investigation of fucosylated serum glycoproteins with application to esophageal adenocarcinoma.

Authors:  Benjamin Mann; Milan Madera; Iveta Klouckova; Yehia Mechref; Lacey E Dobrolecki; Robert J Hickey; Zane T Hammoud; Milos V Novotny
Journal:  Electrophoresis       Date:  2010-06       Impact factor: 3.535

3.  GLI2-mediated melanoma invasion and metastasis.

Authors:  Vasileia-Ismini Alexaki; Delphine Javelaud; Leon C L Van Kempen; Khalid S Mohammad; Sylviane Dennler; Flavie Luciani; Keith S Hoek; Patricia Juàrez; James S Goydos; Pierrick J Fournier; Claire Sibon; Corine Bertolotto; Franck Verrecchia; Simon Saule; Veronique Delmas; Robert Ballotti; Lionel Larue; Philippe Saiag; Theresa A Guise; Alain Mauviel
Journal:  J Natl Cancer Inst       Date:  2010-07-21       Impact factor: 13.506

4.  A complex of novel protease inhibitor, ovostatin homolog, with its cognate proteases in immature mice uterine luminal fluid.

Authors:  Hsien-Lu Huang; Szu-Chin Li; Jin-Fong Wu
Journal:  Sci Rep       Date:  2019-03-21       Impact factor: 4.379

5.  Loss of ADAM9 Leads to Modifications of the Extracellular Matrix Modulating Tumor Growth.

Authors:  Anna N Abety; Elke Pach; Nives Giebeler; Julia E Fromme; Lavakumar Reddy Aramadhaka; Cornelia Mauch; Jay W Fox; Paola Zigrino
Journal:  Biomolecules       Date:  2020-09-07

Review 6.  Oh, the Mutations You'll Acquire! A Systematic Overview of Cutaneous Squamous Cell Carcinoma.

Authors:  Stephenie Droll; Xiaomin Bao
Journal:  Cell Physiol Biochem       Date:  2021-09-22

7.  Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients.

Authors:  Swetlana Mactier; Kimberley L Kaufman; Penghao Wang; Ben Crossett; Gulietta M Pupo; Philippa L Kohnke; John F Thompson; Richard A Scolyer; Jean Y Yang; Graham J Mann; Richard I Christopherson
Journal:  Pigment Cell Melanoma Res       Date:  2014-08-14       Impact factor: 4.693

8.  Detection and Discrimination of Non-Melanoma Skin Cancer by Multimodal Imaging.

Authors:  Sandro Heuke; Nadine Vogler; Tobias Meyer; Denis Akimov; Franziska Kluschke; Hans-Joachim Röwert-Huber; Jürgen Lademann; Benjamin Dietzek; Jürgen Popp
Journal:  Healthcare (Basel)       Date:  2013-10-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.